CareersInvestor RelationsPress RoomCOVID-19
  1. Home
  2. Digital Health Solutions
  3. Digital portfolio overview
  4. Supporting diagnostic and therapeutic decision-making
  5. AI-Pathway Companion Lung Cancer

AI-Pathway Companion Lung CancerActionable insights for personalized care

    Experience superior cancer management with our intelligent clinical decision support solution for the lung cancer pathway1,2

    AI-Pathway Companion focuses on domain expertise ​in the field of oncology and follows, deeply embedded in his DNA, a multi-disease approach along the entire patient journey. The infrastructure layer with its patient data model allows for horizontal integration of patient information​. The ​technology​ enables easy scaling along different oncology pathways and supports physicians in their daily decision-making.

    Through ongoing development and refinement of data interfaces, we aim to increase the number of disease parameters captured throughout the clinical pathway, thereby expanding the relevant data points with the goal of advancing cancer care. We are looking forward to partnering with even more healthcare institutions on optimizing the AI-Pathway Companion solution to their routine clinical practice and preferred lung cancer workflow.

    What´s new with AI-Pathway Companion

    In 2020 we officially presented our first CE-marked pathway – Prostate Cancer3. Now we are expanding the portfolio and we are introducing the AI-Pathway Companion for non-small cell lung cancer2. The solution is all about enabling personalized and standardized decision-making along care pathways. Our mission remains clear: to facilitate diagnosis and therapeutic decisions with a clear goal of improving patient outcomes. 

    Our tools for this are: 

    1. We are enabling advanced oncology care through smart integration of disease-specific, longitudinal data for comprehensive and contextualized decision-making
    2. Facilitate accessibility and adherence to evidence-based standards of care to provide transparency and clinical excellence in oncology
    3. Empowering patient-centered care by leveraging personalized and intelligent insights for well-informed shared decision-making

    Challenges

    Lung cancer is the most diagnosed cancer (11.6% of the total cases) and the leading cause of cancer death (18.4% of the total cancer deaths) among men and women combined4.

    Diagnosing and treating Non-Small Cell Lung Cancer

    DH AI Pathway Companion Infographic

      Clinical Use

      AI-Pathway Companion supports physicians with complex diagnosis and therapeutic decisions within the NSCLC workflow1,4.

      DH AI Pathway Companion Infographics
        AI-Pathway Companion

        AI-Pathway Companion facilitates standardized tumor board preparation and efficient collaboration across specialities

          A comprehensive multidisciplinary team (MDT) program for lung cancer yields improved patient outcomes3

          1. A significant aspect of cancer care is the challenge of preparing and conducting MDTs.
          2. Data is distributed across multiple systems and cannot be easily aggregated or integrated.
          3. The goal is to better capture, organize, and present essential information and to enable advanced analytics and workflow optimizations. 
          4. This can be achieved via digitalization of workflow and standardization of case reviews in a single dashboard accessible by all MDT members. 

          Features and Benefits

          Improving efficiency of MDT discussions in Lung Cancer:

          Adequate patient planning before MDT meeting

          “During lung MDT discussion, it frequently becomes apparent that a key diagnostic report or other crucial information is not yet available. These patients have to be discussed again in the next meeting. This wastes time and effort for all physicians involved in the MDT. A digital assistant, which ensures that the right set of information is available, would substantially increase efficiency”

          Prof. Mathias Prokop4, MD PhD​

          Head of the department Radiology, Nuclear Medicine and Anatomy

          Prof. Mathias Prokop4, MD PhD​

          Head of the department Radiology, Nuclear Medicine and Anatomy

          AI-Patway Companion Status Diagram
          * Based on 901 lung cancer patients scheduled for MDTs in Jan - Dec 2019

            AI-Pathway Companion supports key challenges in diagnosis and treatment of NSCLC by … 1, 3

            Lung Cancer Status
            … providing the ability to have quick snapshot overview
              1

              AI-Pathway Companion consists of several health products and medical devices in their own right and products under development. AI-Pathway Companion is not commercially available in all countries. Their future

              availability cannot be guaranteed. 

              2

              AI-Pathway Companion Lung Cancer VA10A supports Single primary tumor and Non-small cell Lung cancer cases only.

              3AI-Pathway Companion applications are not commercially available in all countries. Their future availability cannot be guaranteed.
              4

              Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

              5Prof. Mathias Prokop is employed by an institution that receives financial support from Siemens Healthineers for collaborations.
              6This function is supported by AI-Pathway Companion Connector.
              7Prerequisite: “All data is available as required per guideline.” Feature dependent on quality of input data.